How Selank Peptide Reduces Anxiety by Modulating GABA Receptors Differently Than Benzodiazepines

What the researchers found

Selank acts as a positive allosteric modulator of GABA receptors, enhancing GABA binding in a concentration-dependent and subtype-selective manner. When combined with benzodiazepines like diazepam or the antipsychotic olanzapine, Selank's effects were not additive — instead, it blocked the modulatory activity of these drugs.

This indicates that Selank's binding site on the GABA receptor is distinct from the benzodiazepine binding site, though the sites may partially overlap. The non-cumulative interaction pattern suggests Selank modulates GABA signaling through a fundamentally different mechanism than conventional anxiolytics.

Why it matters

Anxiety disorders are the most common mental health problems globally, yet the main drugs used (benzodiazepines) cause dependence, cognitive impairment, and sedation. A peptide that targets the same GABA system but through a different mechanism — without these side effects — could represent a fundamentally better approach to anxiety treatment. This study provides the molecular evidence for how Selank achieves this.

How the study worked

The primary method was radioligand-receptor binding analysis using tritium-labeled GABA ([3H]GABA). Researchers isolated brain cell plasma membranes, measured protein concentrations, and assessed how Selank affected GABA binding alone and in combination with benzodiazepines and olanzapine. HPLC was used to verify reagent and Selank purity.

What this study cannot tell us

This was an in vitro receptor binding study using rat brain membranes, not a clinical trial in humans. The study demonstrates a molecular mechanism but does not directly prove this mechanism is responsible for Selank's anti-anxiety effects in living organisms. The partial overlap of binding sites with benzodiazepines needs further structural characterization. Selank's effects on specific GABA receptor subtypes in different brain regions were not fully mapped.

How to read the evidence

This is a basic science study using in vitro radioligand binding assays. While it provides mechanistic insight, the findings are limited to receptor-level interactions in isolated brain membranes and have not been validated in human clinical studies.

When this study was published

Published in 2018, this study provides relatively recent molecular data on Selank's mechanism of action. Selank has been approved for clinical use in Russia since 2009, but mechanistic understanding at the receptor level continues to evolve.

The bigger picture

This study fits within the growing interest in neuropeptides as alternatives to traditional psychiatric drugs. While benzodiazepines have been the standard for anxiety for decades, their side effect profile limits long-term use. Peptide-based anxiolytics like Selank represent a new pharmacological class that could offer anxiety relief through more nuanced modulation of the same receptor systems — targeting specific subtypes without the broad suppression that causes sedation and dependence.

Questions still open

• Which specific GABA receptor subtypes does Selank preferentially modulate, and how does this relate to its anxiolytic vs. nootropic effects?
• Does Selank's ability to block diazepam's effects have clinical implications for patients taking both substances?
• Could Selank's unique binding mechanism be exploited to design improved peptide anxiolytics with even greater selectivity?

Common questions

Read the original research

Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.

Protein and peptide letters, 25(10), 914-923

Citation

Vyunova, Tatiana V; Andreeva, Lioudmila; Shevchenko, Konstantin; Myasoedov, Nikolay. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.. Protein and peptide letters, 25(10), 914-923. https://doi.org/10.2174/0929866525666180925144642